Johnson & Johnson (JNJ)
J&J Seeks FDA Approval for Tremfya for Psoriasis in Kids
Johnson & Johnson JNJ announced that it has filed two supplemental biologics license applications (sBLA) seeking expanded use of its drug Tremfya in pediatric patients.
Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
How To Build A $25,000 Dividend Portfolio, Johnson & Johnson As Your Core Holding
Johnson & Johnson offers investors an effective combination of dividend income and dividend growth, evidenced by its Dividend Yield [TTM] of 3.13% and 5-Year Dividend Growth Rate [CAGR] of 5.61%. The company from the Pharmaceuticals Industry, which has an Aaa credit rating from Moody's, can serve as a strategically important core-position within your dividend portfolio. Allocating the largest proportion of your dividend portfolio to Johnson & Johnson can position your portfolio for reduced volatility and help to decrease its overall risk level.
2 Very Healthy Dividend Stocks to Hold for Decades of Income
Checking a company's vital signs before investing in its stock for dividend income is essential. If the underlying company isn't financially healthy, its dividend probably won't last very long.
J&J Seeks FDA Nod for Subcutaneous Tremfya as Induction Regimen in UC
If approved, JNJ's Tremfya will be the first IL-23 inhibitor to offer a choice of subcutaneous or intravenous use as induction treatment in ulcerative colitis.
2 Unstoppable Dividend Stocks to Buy Now With $500
2 Unstoppable Dividend Stocks to Buy Now With $500
3 Dividend Kings So You Can Sleep Well At Night
Dividend Kings, like Coca-Cola, Johnson & Johnson, and Walmart, are prime long-term investments due to their consistent dividend growth over 50+ years. Coca-Cola offers a 3% yield and strong EBITDA growth, making it a solid buy despite recent stock volatility and health-related headwinds. Johnson & Johnson, despite legal issues, remains undervalued with a 3.2% yield and robust free cash flow, making it an attractive investment.
Which Is A Better Pick: JNJ Stock Or AbbVie?
Given its better prospects, we believe that AbbVie stock (NYSE: ABBV) is currently a better pharmaceutical pick over Johnson & Johnson stock (NYSE: JNJ). Both AbbVie and J&J trade at 15x forward expected earnings.
J&J Loses Around $24B in a Month: How to Play the Stock?
The decline in J&J's share price and the drug/biotech sector's downturn in the past month have left investors wondering if they should sell J&J stock.
Johnson & Johnson: Policy Uncertainty Elevated, But Shares Remain Inexpensive
The Health Care sector faces uncertainty due to speculation about Robert F. Kennedy, Jr. leading HHS, impacting stocks like Johnson & Johnson. Despite solid earnings, JNJ shares have been under pressure; I maintain a buy rating due to undervaluation and a strong dividend yield. Key risks include health care policy changes, global economic conditions, and competition, but JNJ's revenue and earnings forecasts remain optimistic.
Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Johnson & Johnson (JNJ). This makes it worthwhile to examine what the stock has in store.
J&J's skin disease drug meets main goals of late-stage study
Johnson & Johnson's drug for a type of skin condition met the main goals in a late-stage trial, the drugmaker said on Monday.
